The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O

Drug-associated acute lung injury: a population-based cohort study.

Chest. 2012;142(4):845-850

Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS

Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

The Korean journal of internal medicine. 2010;25(1):86-92

Peerzada MM, Spiro TP, Daw HA

Pulmonary toxicities of biologics: a review.

Anti-cancer drugs. 2010;21(2):131-9

Bitzan M, Anselmo M, Carpineta L

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Pediatric pulmonology. 2009;44(9):922-34

Lioté H, Lioté F, Séroussi B, Mayaud C, Cadranel J

Rituximab-induced lung disease: A systematic literature review.

The European respiratory journal. 2010;35(3):681-7

Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P

The late adverse events of rituximab therapy--rare but there!

Leukemia & lymphoma. 2009;50(7):1083-95

Montero AJ, McCarthy JJ, Chen G, Rice L

Acute respiratory distress syndrome after rituximab infusion.

International journal of hematology. 2005;82(4):324-6

Ghesquieres H

Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology. 2005;16(8):1399

Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S

Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma.

International journal of hematology. 2004;80(2):164-7